Similar articles

• Tyrosine kinase signal transduction inhibitors. Clinical trials.

  Scagliotti GV. Scagliotti GV. Suppl Tumori. 2002 Jul-Aug;1(4):S34-6. Suppl Tumori. 2002. PMID: 12415814 Review. No abstract available.
• EGFR inhibition in NSCLC: the emerging role of cetuximab.

  Herbst RS. Herbst RS. J Natl Compr Canc Netw. 2004 Sep;2 Suppl 2:S41-51. J Natl Compr Canc Netw. 2004. PMID: 19780245 Review.
• The rational basis of using novel targeted biological agents in non-small cell lung cancer.

  Ciardiello F. Ciardiello F. Suppl Tumori. 2002 Jul-Aug;1(4):S31-3. Suppl Tumori. 2002. PMID: 12415813 Review. No abstract available.
• Targeting the epidermal growth factor receptor a new strategy in cancer treatment.

  Gianni L, Grasselli G. Gianni L, et al. Suppl Tumori. 2002 Jul-Aug;1(4):S60-1. Suppl Tumori. 2002. PMID: 12415824 Review. No abstract available.
• Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.

  Friedrich MJ. Friedrich MJ. J Natl Cancer Inst. 2009 Aug 5;101(15):1039-41. doi: 10.1093/jnci/djp243. Epub 2009 Jul 28. J Natl Cancer Inst. 2009. PMID: 19638503 No abstract available.